Damora Therapeutics is trading 5.02% higher at $22.68, with no current company-specific catalyst identified.
- The price context shows a move from the November 2 close of $21.60.
- CNBC reports no recent news for the stock; Damora’s CEO appointment news is from March, not November 3.
- The Nasdaq Composite is up 0.65%, offering a possible broad-market tailwind, but the evidence does not establish it as the direct cause.